Healthcare provider profile · identity verified

Regina Wang, M.D.

Family Practice · RANCHO CUCAMONGA, CA · NPI 1093246472

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	401	193
Levothyroxine Sodium	Levothyroxine Sodium	219	103
Amlodipine Besylate	Amlodipine Besylate	210	110
Losartan Potassium	Losartan Potassium	194	94
Lisinopril	Lisinopril	193	100
Rosuvastatin Calcium	Rosuvastatin Calcium	170	87
Omeprazole	Omeprazole	131	70
Metformin Hcl	Metformin Hcl	117	61
Atenolol	Atenolol	113	57
Potassium Chloride	Potassium Chloride	109	62
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	99	51
Meloxicam	Meloxicam	97	60
Simvastatin	Simvastatin	96	48
Pantoprazole Sodium	Pantoprazole Sodium	88	40
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	84	40
Alendronate Sodium	Alendronate Sodium	81	39
Furosemide	Furosemide	81	41
Albuterol Sulfate Hfa	Albuterol Sulfate	79	61
Hydrochlorothiazide	Hydrochlorothiazide	78	47
Ibuprofen	Ibuprofen	78	42
Metformin Hcl Er	Metformin Hcl	76	34
Metoprolol Tartrate	Metoprolol Tartrate	75	40
Gabapentin	Gabapentin	68	47
Glipizide	Glipizide	67	37
Trazodone Hcl	Trazodone Hcl	62	37
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	55	23
Hydralazine Hcl	Hydralazine Hcl	54	28
Pradaxa	Dabigatran Etexilate Mesylate	51	27
Jardiance	Empagliflozin	49	24
Azelastine Hcl	Azelastine Hcl	45	16
Bisoprolol Fumarate	Bisoprolol Fumarate	40	22
Duloxetine Hcl	Duloxetine Hcl	40	21
Ozempic	Semaglutide	40	13
Tamsulosin Hcl	Tamsulosin Hcl	35	23
Montelukast Sodium	Montelukast Sodium	33	20
Clopidogrel	Clopidogrel Bisulfate	31	19
Fluoxetine Hcl	Fluoxetine Hcl	31	18
Lorazepam	Lorazepam	31	14
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	31	18
Finasteride	Finasteride	30	13
Hydrocortisone	Hydrocortisone	30	17
Sertraline Hcl	Sertraline Hcl	29	14
Metoprolol Succinate	Metoprolol Succinate	28	11
Sumatriptan Succinate	Sumatriptan Succinate	28	suppressed
Terazosin Hcl	Terazosin Hcl	28	14
Ondansetron Odt	Ondansetron	27	19
Tramadol Hcl	Tramadol Hcl	27	14
Carvedilol	Carvedilol	26	12
Allopurinol	Allopurinol	25	17
Ezetimibe	Ezetimibe	25	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	25	13
Cephalexin	Cephalexin	23	18
Prednisone	Prednisone	23	21
Wixela Inhub	Fluticasone Propion/Salmeterol	23	12
Famotidine	Famotidine	22	11
Spironolactone	Spironolactone	22	12
Trospium Chloride	Trospium Chloride	21	suppressed
Eliquis	Apixaban	20	suppressed
Humulin N	Insulin Nph Human Isophane	20	12
Venlafaxine Hcl Er	Venlafaxine Hcl	20	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	19	suppressed
Naproxen	Naproxen	19	14
Propranolol Hcl	Propranolol Hcl	19	suppressed
Fluticasone Propionate	Fluticasone Propionate	18	12
Pravastatin Sodium	Pravastatin Sodium	18	suppressed
Estradiol	Estradiol	17	14
Humulin R	Insulin Regular, Human	17	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	17	suppressed
Baclofen	Baclofen	16	suppressed
Methocarbamol	Methocarbamol	16	suppressed
Terbinafine Hcl	Terbinafine Hcl	16	11
Triamcinolone Acetonide	Triamcinolone Acetonide	15	13
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	14	14
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	14	suppressed
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Warfarin Sodium	Warfarin Sodium	14	suppressed
Fenofibrate	Fenofibrate	13	suppressed
Azithromycin	Azithromycin	12	12
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Donepezil Hcl	Donepezil Hcl	12	suppressed
Alvesco	Ciclesonide	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed
Pilocarpine Hcl	Pilocarpine Hcl	11	suppressed
Retin-A	Tretinoin	11	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error